> ## Content Index
> Fetch the complete content index at: https://www.fdaweb.com/llms.txt
> Use this file to discover other available public pages before exploring further.

# Tecentriq Plus Avastin Misses in Ovarian Cancer Trial
- URL: https://www.fdaweb.com/tecentriq-plus-avastin-misses-in-ovarian-cancer-trial/
- Published: 2020-07-13T12:00:00.000Z
- Updated: 2026-09-14T16:20:55.000Z
- Author: David McFarland
- Tags: Drugs, #legacy-id-D5147179

Genentech says the Phase 3 IMagyn050 study showed that the addition of Tecentriq (atezolizumab) to Avastin (bevacizumab), paclitaxel and carboplatin did not meet its primary endpoint of progression-free survival for front-line treatment of women with newly-diagnosed advanced-stage ovarian cancer. The company says safety data indicated that the combination therapy was consistent with the known safety profile. 

Data on overall survival, which is a co-primary endpoint, are currently “immature” and follow-up will continue until the next planned analysis. Results from the study will be “further evaluated in order to inform the Tecentriq gynecological development program,” it says. “The Tecentriq program in ovarian cancer and cervical cancers builds on the combination with Avastin, which has helped women with newly diagnosed, advanced or relapsed ovarian and cervical cancers live without their disease getting worse, as demonstrated in results across seven pivotal Phase 3 trials that involved more than 5,000 women.”  

Genentech says its development program, which includes multiple ongoing and planned Phase 3 studies, is evaluating Tecentriq, both alone and in combination with other drugs, across lung, genitourinary, skin, breast, gastrointestinal, gynecological, and head and neck cancers.